Trial of Deferiprone in Parkinson’s Disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00127673" target="_blank" >RIV/00216224:14110/22:00127673 - isvavai.cz</a>
Result on the web
<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2209254" target="_blank" >https://www.nejm.org/doi/full/10.1056/NEJMoa2209254</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa2209254" target="_blank" >10.1056/NEJMoa2209254</a>
Alternative languages
Result language
angličtina
Original language name
Trial of Deferiprone in Parkinson’s Disease
Original language description
BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
Czech name
—
Czech description
—
Classification
Type
J<sub>ost</sub> - Miscellaneous article in a specialist periodical
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
The New England Journal of medicine
ISSN
1533-4406
e-ISSN
1533-4406
Volume of the periodical
387
Issue of the periodical within the volume
NA
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
2045-2055
UT code for WoS article
—
EID of the result in the Scopus database
—